Zobrazit minimální záznam

Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?

dc.contributor.authorZuna, Jan
dc.contributor.authorHovorková, Lenka
dc.contributor.authorKrotká, Justina
dc.contributor.authorWinkowska, Lucie
dc.contributor.authorNovak, Zbynek
dc.contributor.authorŠrámková, Lucie
dc.contributor.authorStarý, Jan
dc.contributor.authorTrka, Jan
dc.contributor.authorCazzaniga, Giovanni
dc.contributor.authorCario, Gunnar
dc.contributor.authorŽaliová, Markéta
dc.date.accessioned2023-12-20T13:40:42Z
dc.date.available2023-12-20T13:40:42Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2140
dc.description.abstractWe read with a great interest the paper focused on different minimal residual disease (MRD) approaches and its significance in Ph+ acute lymphoblastic leukemia (ALL) patients, authored by Short et al. from the MD Anderson Cancer Center. We would like to thank the authors for this important data, and offer a short comment from our pediatric experience.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1002/ajh.27022
dc.rightsThis is the peer reviewed version of the following article: [Zuna J, Hovorkova L, Zaliova M. Posttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track? Am J Hematol. 2023 Oct;98(10):E269-E271. Jul 14. PMID: 37449465.], which has been published in final form at [https://doi.org/10.1002/ajh.27022]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.
dc.titlePosttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?en
dcterms.accessRightsembargoedAccess
dcterms.licensehttps://authorservices.wiley.com/author-resources/Journal-Authors/licensing/self-archiving.html
dc.date.updated2025-01-15T10:12:08Z
dc.subject.keywordBCR::ABL1en
dc.subject.keywordacute lymphoblastic leukemiaen
dc.identifier.eissn1096-8652
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-03-00128
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/FN/I-FN/I-FNM
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MZ0/NU/NU21-03-00128
dc.date.embargoStartDate2025-01-15
dc.date.embargoEndDate2024-07-14
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.identifier.doi10.1002/ajh.27022
dc.identifier.utWos001029819700001
dc.identifier.eidScopus2-s2.0-85165292273
dc.identifier.obd633494
dc.identifier.rivRIV/00216208:11130/23:10465834
dc.identifier.pubmed37449465
dc.subject.rivPrimary30000::30200::30205
dc.subject.rivSecondary30000::30200::30204
dcterms.isPartOf.nameAmerican Journal of Hematology
dcterms.isPartOf.issn0361-8609
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume98
dcterms.isPartOf.journalIssue10
uk.faculty.primaryId109
uk.faculty.primaryName2. lékařská fakultacs
uk.faculty.primaryNameSecond Faculty of Medicineen
uk.faculty.secondaryId52
uk.faculty.secondaryNameFakultní nemocnice v Motolecs
uk.faculty.secondaryNameMotol University Hospitalen
uk.department.primaryId109
uk.department.primaryName2. lékařská fakultacs
uk.department.primaryNameSecond Faculty of Medicineen
uk.department.secondaryId1675
uk.department.secondaryId100010692507
uk.department.secondaryNameKlinika dětské hematologie a onkologiecs
uk.department.secondaryNameKlinika dětské hematologie a onkologieen
uk.department.secondaryNameKlinika dětské hematologie a onkologie 2. LF UK a FN Motolcs
uk.department.secondaryNameDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine and Motol University Hosen
dc.description.pageRangeE269-E271
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::letter to the editorscs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::letter to the editorsen
dc.type.obdHierarchyCode73::152::233en
uk.displayTitlePosttreatment positivity of BCR::ABL1 in acute lymphoblastic leukemia: Should we keep track?en


Soubory tohoto záznamu

Thumbnail
Název:
Letter_Am J Hematol_2023_prepr ...
Velikost:
322.3Kb
Formát:
PDF
Zobrazit/otevřít

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam